Symbiotec Pharmalab IPO
Pharmaceuticals • ₹1757 Cr
Medium risk because:
- 5 material risk factors disclosed in DRHP
- High customer concentration flagged in the DRHP
- Regulatory or legal risks cited in DRHP
IPOFins risk score from DRHP risk factors, subscription demand & issue structure
Price Band
₹988
Lot Size
15 shares
Issue Size
₹1757 Cr
Open
24 Aug 2026
Close
27 Aug 2026
Subscription
71.2×
IPO Schedule
| Issue Open Date | 24 Aug 2026 |
| Issue Close Date | 27 Aug 2026 |
| Allotment Date | 28 Aug 2026 |
| Listing Date | 31 Aug 2026 |
About Symbiotec Pharmalab
Symbiotec Pharmalab is a pharmaceutical and biotechnology company involved in the development and manufacturing of active pharmaceutical ingredients (APIs), biotechnology products, and complex injectables. Its operations span three platforms — organic chemistry, biotechnology, and complex injectables. The company has a portfolio of over 60 corticosteroid and steroid hormone APIs, including hydrocortisones, betamethasone, methylprednisolones, progesterones, estrogens, and testosterone. It also provides contract development and manufacturing organisation (CDMO) services to pharmaceutical and nutraceutical companies. As of March 31, 2026, the company had two operational API manufacturing facilities at Rau and Pithampur in Madhya Pradesh. It has also commissioned a biomanufacturing facility at Ujjain and a complex injectables facility at Mhow, Madhya Pradesh. The company operates three R&D centres in Indore focused on organic chemistry, biotechnology and complex injectables. Its products and services have been supplied to over 200 customers across more than 40 countries. Use of proceeds: The IPO consists of both a fresh issue and an offer for sale. Proceeds from the offer for sale segment will be directed to the respective selling shareholders, whereas the net proceeds from the fresh issue will be utilised for the following purposes: Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company — Rs 112.5 crore General corporate purposes
Company Details
Founders / Promoters
Mr. Anil Satwani
Founded
2002
Registrar
LINK
Documents
DRHP / RHP Document (PDF)
View official prospectus →
Investment Analysis
Symbiotec Pharmalab — IPOFins Verdict
QuantitativeDriven by QIB demand at 172.0x and moderate disclosed risk (5/10), Symbiotec Pharmalab listed at a premium of 0.0% to its issue price. The signals lean constructive — still confirm valuation against listed peers and read the DRHP before applying beyond one lot.
- The company had a global volume market share of 38.2% in corticosteroid APIs and 23.8% in steroidal-hormone APIs in FY26, excluding androstenedione and hydroxyprogesterone caproate. It also had market
- The company has a portfolio of over 60 corticosteroid and steroidal-hormone APIs across sterile and non-sterile formats. As of March 31, 2026, its portfolio covered approximately 90% of corticosteroid
- The company has a presence across domestic and international markets, with revenue from customers outside India at Rs 582.64 crore, Rs 414.78 crore, and Rs 429.52 crore in FY26, FY25, and FY24, respec
- The company claims to have a vertically integrated and multi-scale manufacturing platform. As of March 31, 2026, its facilities had an aggregate maximum chemical synthesis capacity of 584.67 MT, a fer
- The company's Rau and Pithampur facilities have approvals from regulatory authorities including the US FDA, EU-GMP, and WHO-GMP.
Score breakdown — what drove this verdict
Moderate risk from DRHP → score +0.0
Institutional subscription → score +2.0
Strong retail interest → score +0.5
Actual listing outcome → score −0.5
Base score: 5.0 · Final score = base + all factor adjustments, capped 1–10. Full methodology →
IPOFins Score is a quantitative signal from subscription demand, disclosed risk, and listing data — not investment advice. Not SEBI-registered.
Listing Performance
Issue Price
₹988
Listing Price
₹988
Listing Gain/Loss
+0.00%
Listing Date
31 Aug 2026
Price Since Listing
Returns are measured against the ₹988 issue price.
Listing
₹988
+0.0%
1 Week
₹1,098.7
+11.2%
Current
₹1,124.35
+13.8%
Want to buy this stock?
Trade Symbiotec Pharmalab on the secondary market
FAQ
What is the price band of Symbiotec Pharmalab IPO?
The price band is ₹988 per share with a lot size of 15 shares. Minimum investment: ₹14,820.
What does Symbiotec Pharmalab do?
Symbiotec Pharmalab is a pharmaceutical and biotechnology company involved in the development and manufacturing of active pharmaceutical ingredients (APIs), biotechnology products, and complex injectables. Its operations span three platforms — organic chemistry, biotechnology, and complex injectables. The company has a portfolio of over 60 corticosteroid and steroid hormone APIs, including hydrocortisones, betamethasone, methylprednisolones, progesterones, estrogens, and testosterone. It also provides contract development and manufacturing organisation (CDMO) services to pharmaceutical and nutraceutical companies. As of March 31, 2026, the company had two operational API manufacturing facilities at Rau and Pithampur in Madhya Pradesh. It has also commissioned a biomanufacturing facility at Ujjain and a complex injectables facility at Mhow, Madhya Pradesh. The company operates three R&D centres in Indore focused on organic chemistry, biotechnology and complex injectables. Its products and services have been supplied to over 200 customers across more than 40 countries. Use of proceeds: The IPO consists of both a fresh issue and an offer for sale. Proceeds from the offer for sale segment will be directed to the respective selling shareholders, whereas the net proceeds from the fresh issue will be utilised for the following purposes: Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company — Rs 112.5 crore General corporate purposes
Should I apply for Symbiotec Pharmalab IPO?
Symbiotec Pharmalab listed at ₹988 (+0.0% premium to the ₹988 issue price) after 71.2x subscription. IPOFins Score 7/10: Driven by QIB demand at 172.0x and moderate disclosed risk (5/10), Symbiotec Pharmalab listed at a premium of 0.0% to its issue price. The signals lean constructive — still confirm valuation against listed peers and read the DRHP before applying beyond one lot.
Who founded Symbiotec Pharmalab?
Symbiotec Pharmalab was founded by Mr. Anil Satwani in 2002.